261 related articles for article (PubMed ID: 21680759)
1. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.
Guenova E; Teske A; Fehrenbacher B; Hoerber S; Adamczyk A; Schaller M; Hoetzenecker W; Biedermann T
Arch Dermatol; 2011 Oct; 147(10):1203-5. PubMed ID: 21680759
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab for pyoderma gangrenosum.
Kluger N
Arch Dermatol; 2012 May; 148(5):655; author reply 656. PubMed ID: 22782165
[No Abstract] [Full Text] [Related]
3. Pyoderma gangrenosum: study of 21 patients and proposal of a 'clinicotherapeutic' classification.
Marzano AV; Trevisan V; Lazzari R; Crosti C
J Dermatolog Treat; 2011 Oct; 22(5):254-60. PubMed ID: 20666672
[TBL] [Abstract][Full Text] [Related]
4. Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum.
Marzano AV; Trevisan V; Lazzari R; Crosti C
J Dermatolog Treat; 2010 May; 21(3):140-3. PubMed ID: 19903010
[TBL] [Abstract][Full Text] [Related]
5. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody.
Dini V; Romanelli M; Bertone M; Talarico S; Bombardieri S; Barachini P
Int J Low Extrem Wounds; 2007 Jun; 6(2):108-13. PubMed ID: 17558009
[TBL] [Abstract][Full Text] [Related]
6. A case of granulomatosis with polyangiitis and pyoderma gangrenosum successfully treated with infliximab and rituximab.
Donmez S; Pamuk ON; Gedik M; A K R; Bulut G
Int J Rheum Dis; 2014 May; 17(4):471-5. PubMed ID: 24460826
[TBL] [Abstract][Full Text] [Related]
7. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
[TBL] [Abstract][Full Text] [Related]
9. A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents.
Duchini G; Itin P; Arnold A
Adv Skin Wound Care; 2011 May; 24(5):217-20. PubMed ID: 21505282
[TBL] [Abstract][Full Text] [Related]
10. [Pyoderma gangrenosum associated with hidradenitis suppurativa: a case report and review of the literature].
García-Rabasco AE; Esteve-Martínez A; Zaragoza-Ninet V; Sánchez-Carazo JL; Alegre-de-Miquel V
Actas Dermosifiliogr; 2010 Oct; 101(8):717-21. PubMed ID: 20965015
[TBL] [Abstract][Full Text] [Related]
11. Pyoderma gangrenosum following breast reduction: treatment with topical tacrolimus and steroids.
Doren EL; Aya-ay ML
Aesthet Surg J; 2014 Mar; 34(3):394-9. PubMed ID: 24448967
[TBL] [Abstract][Full Text] [Related]
12. Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
Hubbard VG; Friedmann AC; Goldsmith P
Br J Dermatol; 2005 May; 152(5):1059-61. PubMed ID: 15888172
[TBL] [Abstract][Full Text] [Related]
13. What do autoinflammatory syndromes teach about common cutaneous diseases such as pyoderma gangrenosum? A commentary.
Butler D; Shinkai K
Dermatol Clin; 2013 Jul; 31(3):427-35. PubMed ID: 23827245
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic hotline. Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report.
Baglieri F; Scuderi G
Dermatol Ther; 2010; 23(5):541-3. PubMed ID: 20868408
[TBL] [Abstract][Full Text] [Related]
15. Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab.
Low ZM; Mar A
Australas J Dermatol; 2018 May; 59(2):131-134. PubMed ID: 29205260
[TBL] [Abstract][Full Text] [Related]
16. Ustekinumab for peristomal pyoderma gangrenosum.
Fahmy M; Ramamoorthy S; Hata T; Sandborn WJ
Am J Gastroenterol; 2012 May; 107(5):794-5. PubMed ID: 22552250
[No Abstract] [Full Text] [Related]
17. Clinical features and management of parastomal pyoderma gangrenosum in inflammatory bowel disease.
Uchino M; Ikeuchi H; Matsuoka H; Bando T; Takahashi Y; Takesue Y; Matsumoto T; Tomita N
Digestion; 2012; 85(4):295-301. PubMed ID: 22584791
[TBL] [Abstract][Full Text] [Related]
18. Treatment of pyoderma gangrenosum with etanercept.
McGowan JW; Johnson CA; Lynn A
J Drugs Dermatol; 2004; 3(4):441-4. PubMed ID: 15303791
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology of pyoderma gangrenosum (PG): an updated review.
Braswell SF; Kostopoulos TC; Ortega-Loayza AG
J Am Acad Dermatol; 2015 Oct; 73(4):691-8. PubMed ID: 26253362
[TBL] [Abstract][Full Text] [Related]
20. A case of vulvar pyoderma gangrenosum associated with collagenous colitis.
Roé E; Dalmau J; García-Navarro X; Corella F; Monfort D; Busquets D; Ribé A; Delgado E; Alomar A
Dermatology; 2006; 213(3):234-5. PubMed ID: 17033174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
